Clinical Trials Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Sep 28, 2019; 25(36): 5530-5542
Published online Sep 28, 2019. doi: 10.3748/wjg.v25.i36.5530
Table 1 Inclusion and exclusion criteria
Inclusion criteriaExclusion criteria
Patients over the age of 18 yr, male or femaleContraindications to perform digestive endoscopy
Cystic tumor of the pancreas > 15 mm to benefit from a puncture under EUS control to determine the etiological and gravity diagnosis.Hemorrhagic disease, hemostasis or coagulation disorder (PR < 60%, APTT > 40 s or platelets < 60000/mm3).
No transient shutdown of AVK, AOD or AAP
Complete clinical examination
Patients able to follow and understand the study and answer the questionnaire
Pregnant or lactating women (a urine pregnancy test was carried out in women of childbearing age)
Informed and written consentVulnerable persons: deprived of liberty or guardianship
Affiliation to a social security
Table 2 Pathologic features of surgical resections and mutational analysis of cystic fluid and neoplastic tissue
Final diagn-osisPat. codeGenderAgeStatusSampleProportion of mutated allele
Patholo-gical feature-s
Cancer1F73No mutatio-nCF--------MCN with invasive ADK
Cancer9M72Noncon-cordant mutatio-nsCF0--00---IPMN with invasive adenoca-rcinoma pT2N1
Cancer10F60Conc-ordant mutatio-nsCF5------50IPMN with invasive adenoca-rcinoma pT3N1
Cancer13M66Concor-dant mutatio-nsCF3-1-----IPMN with invasive adenoca-rcinoma pT3N1
Cancer14M63Concor-dant mutatio-nsCF-37------MCN with invasive ADK
Cancer15M83Concor-dant mutatio-nsCF3250------IPMN with focal adenoca-rcinoma pTisN0
Cancer17F71Concor-dant mutatio-nsCF2548---56--IPMN with focal adenoca-rcinoma pTisN0
Cancer18M82Concor-dant mutatio-nsCF41-----39-IPMN with focal adenoca-rcinoma pTisN0
Cancer19F67Concor-dant mutatio-nsCF23-31-----MCN with invasive ADK
NO Cancer2M86No mutatio-nCF--------IPMN with low-grade dysplasi-a
NO Cancer3M75No mutatio-nCF--------Serous cystaden-oma
NO Cancer4F66No mutatio-nCF--------IPMN with low-grade dysplasi-a
NO Cancer8F81No mutatio-nCF--------Mucinou-s cystaden-oma
NO Cancer16M63No mutatio-nCF--------Cystic lymphan-gioma
NO Cancer6M71Nonconc-ordant mutatio-nsCF1231------IPMN with low-grade dysplasi-a
NO Cancer5M74Concor-dant mutatio-nsCF4112------IPMN with low-grade dysplasi-a
NO Cancer20M51Concor-dant mutatio-nsCF-26------IPMN with low-grade dysplasi-a
Table 3 KRAS/GNAS mutations in cystic fluid and final diagnosis
KRAS/GNAS mutations analysis in cystic fluid, n = 17CancerNo cancer
Positive mutations (+)
Population size, n73
Patient codesTrue positive: 10, 13, 14, 15, 17, 18, 19False positive: 5, 6, 20
Negative mutations (-)
Population size, n25
Patient codesFalse negative: 1, 9True negative: 2, 3, 4, 8, 16
Total population, n98
Table 4 RAF/PTPRD/CTNNB1/RNF43/POLD1/TP53 mutations in cystic fluid and final diagnosis
RAF/PTPRD/CTNNB1/RNF43/POLD1/TP53 mutations in cystic fluid, n = 17CancerNo cancer
Positive (+)
Population size, n50
Patient codesTrue positive: 10, 13, 17, 18, 19False positive
Negative mutations (-)
Population size, n48
Patient codesFalse negative: 1, 9, 14, 15True negative: 2, 3, 4, 5, 6, 8, 16, 20
Total population, n98